National Association of Chain Drug Stores Marketplace Meeting
PHOENIX, June 17 /PRNewswire-FirstCall/ --
Gum Tech International, Inc. (Nasdaq: GUMM), the developer and distributor of
Zicam(R) Cold Remedy and Zicam Allergy Relief, has introduced five new Zicam
products at the National Association of Chain Drug Stores (NACDS) Marketplace
meeting, taking place June 15-18, 2002 in San Diego, California.
The new cough and cold products will build on the successful Zicam
franchise and are based on formulas using Gum Tech's patented, proprietary
nasal gel matrix technology, said Carl J. Johnson, president and chief
executive officer of Gum Tech International, Inc. The new products include:
Zicam Cold Remedy Swabs, Zicam Kids Size Cold Remedy Swabs, Zicam Extreme
Congestion Relief, Zicam Sinus Relief, and Zicam Nasal Moisturizer.
"These are the first of an array of new products from Gum Tech," said Mr.
Johnson. "We intend to continue developing and marketing innovative,
over-the-counter drug application and delivery systems, offering consumers
ready access to effective, reasonably-priced healthcare products."
About Gum Tech International, Inc.
Gum Tech International, Inc. (Nasdaq: GUMM) is an innovative nutrient and
drug delivery technology company engaged in the development, manufacture and
marketing of delivery systems for bioactive compounds. Gel Tech, LLC, its
wholly owned subsidiary, produces, markets and sells Zicam(R) Cold Remedy
nasal gel, a patented, homeopathic remedy that significantly reduces the
duration and severity of the common cold; and Zicam Allergy Relief nasal gel,
a homeopathic remedy designed to provide relief to allergy sufferers.
This news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995, including statements
regarding future new product development the Company intends to pursue and
benefits to consumers. These forward-looking statements are based on the
Company's expectations and are subject to a number of risks and uncertainties,
many of which cannot be predicted or quantified and are beyond the Company's
control. Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking statements.
Some factors that could cause actual results to differ materially from the
Company's expectations include difficulties and delays in introducing,
manufacturing and marketing the Company's new products, lack of market
acceptance for such products, and the introduction of rival products. Other
factors that could cause actual results to differ materially from the
Company's expectations are described in the Company's Annual Reports on Form
10-K filed pursuant to the Securities and Exchange Act of 1934 in the section
entitled "Management's Discussion and Analysis of Financial Condition and
Results of Operations" under the subheading "Risk Factors" filed pursuant to
the Securities Exchange Act of 1934.
Zicam is a registered trademark of Gum Tech International, Inc.
MAKE YOUR OPINION COUNT - Click Here
tbutton.prnewswire.com
SOURCE Gum Tech International, Inc.
-0- 06/17/2002
/CONTACT: Investor, Susan Bryan of Christensen & Associates,
+1-602-870-4752, sbryan@cabestpractice.com, for Gum Tech International, Inc.;
or Media, Lorie Fiber, +1-323-202-1046, lorie.fiber@edelman.com, or Regina
Novickis, +1-323-202-1027, regina.novickis@edelman.com, both of Edelman PR
Worldwide, for Gum Tech International, Inc./
(GUMM) |
